Phoenix Biotech Acquisition Stock Return On Asset
Phoenix Biotech Acquisition fundamentals help investors to digest information that contributes to Phoenix Biotech's financial success or failures. It also enables traders to predict the movement of Phoenix Stock. The fundamental analysis module provides a way to measure Phoenix Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phoenix Biotech stock.
Phoenix |
Phoenix Biotech Acquisition Company Return On Asset Analysis
Phoenix Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Phoenix Biotech Return On Asset | -0.0255 |
Most of Phoenix Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phoenix Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Phoenix Biotech Acquisition has a Return On Asset of -0.0255. This is 94.57% lower than that of the Capital Markets sector and significantly lower than that of the Financials industry. The return on asset for all United States stocks is 81.79% lower than that of the firm.
Phoenix Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phoenix Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phoenix Biotech could also be used in its relative valuation, which is a method of valuing Phoenix Biotech by comparing valuation metrics of similar companies.Phoenix Biotech is currently under evaluation in return on asset category among its peers.
Phoenix Fundamentals
Return On Asset | -0.0255 | |||
Current Valuation | 66.05 M | |||
Number Of Shares Shorted | 86 | |||
Net Income | (2.52 M) | |||
Cash And Equivalents | 553.77 K | |||
Cash Per Share | 0.02 X | |||
Total Debt | 650 K | |||
Current Ratio | 13.88 X | |||
Book Value Per Share | (2.20) X | |||
Cash Flow From Operations | (1.71 M) | |||
Short Ratio | 1.62 X | |||
Beta | 0.044 | |||
Total Asset | 42.37 M | |||
Retained Earnings | (10.76 M) | |||
Working Capital | 11.62 M | |||
Z Score | -0.03 | |||
Net Asset | 42.37 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |